Mark Robinson

PublicAcquisitionMergerMajority

target

Avexis

bidder

Novartis

£5,275m

60 dealmakers

AcquisitionPublic

target

Pharmacyclics Inc.

bidder

Abbvie

£13,661m

4 dealmakers

AcquisitionPublic

target

Receptos Inc.

bidder

Celgene Corporation

£4,639m

4 dealmakers

Public

target

Tobira Therapeutics

bidder

Allergan

value n/a

1 dealmaker

AcquisitionPublicMerger

target

Tesaro

bidder

Glaxosmithkline

£3,371m

41 dealmakers

PrivateAcquisitionMajorityPrivate Equity

Medical Equipment

target

Auris Health

bidder

ETHICON

£2,640m

52 dealmakers

PublicMergerAcquisitionMajority

target

Spark Therapeutics

bidder

Roche Holdings

£3,291m

29 dealmakers

MergerAcquisitionPublicMajorityDomestic

target

Array Biopharma

bidder

Pfizer

£9,049m

51 dealmakers

PublicAcquisitionMergerPrivate Equity

target

Alder Biopharmaceuticals

bidder

Lundbeck As

£1,559m

10 dealmakers

AcquisitionPublicMajority

target

Audentes Therapeutics

bidder

Astellas Pharma

£2,318m

73 dealmakers

AcquisitionPublicMajorityTender Offer

target

Forty Seven

bidder

Gilead Sciences

£3,821m

48 dealmakers

MajorityPublicAcquisitionTender Offer

target

Portola Pharmaceuticals

bidder

Alexion Pharmaceuticals

£1,306m

50 dealmakers

PublicMajorityAcquisitionDomestic

target

Momenta Pharmaceuticals

bidder

Johnson & Johnson

£4,929m

57 dealmakers

MajorityDomesticPublicAcquisitionTender Offer

target

IMMUNOMEDICS

bidder

Gilead Sciences

£16,407m

50 dealmakers

MajorityDomesticAcquisitionTender OfferPublic

target

MYOKARDIA

bidder

Bristol Myers Squibb Company

£10,012m

54 dealmakers

PublicCross BorderAcquisitionMajority

target

Osi Pharmaceuticals

bidder

Astellas Pharma

£3,287m

4 dealmakers

United Kingdom

AcquisitionMajorityPublicMergerCross Border

target

Gw Pharmaceuticals

bidder

Jazz Pharmaceuticals

£5,266m

85 dealmakers